Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafamidis

FDA-approved product (capsule, oral), marketed as Vyndamax, Vyndaqel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tafamidis
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AL amyloidosis
  • Amyloidosis
  • Cardiomyopathy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafamidis in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafamidis with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

    NCT05635045 · start 2022-07-08

    Registered record
    Registry ID
    NCT05635045
    Conditions
    Transthyretin Amyloidosis
    Interventions
    I 124-Evuzamitide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-08
    Completion
    2024-06-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis
    InterventionI 124-Evuzamitide
    PhasePhase 2
    Registry statusCompleted

  • Amyloidosis TTR Flow Reserve Evaluation

    NCT05103943 · start 2022-02-24

    Registered record
    Registry ID
    NCT05103943
    Conditions
    Amyloid Cardiomyopathy
    Interventions
    SPECT MPI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2022-02-24
    Completion
    2026-12-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloid Cardiomyopathy
    InterventionSPECT MPI
    PhaseNot applicable
    Registry statusActive not recruiting

  • carDIo-ttranSSfOrm nucLEar Imaging Study

    NCT05259072 · start 2022-01-19

    Registered record
    Registry ID
    NCT05259072
    Conditions
    Amyloidosis; Transthyretin Amyloid Cardiomyopathy
    Interventions
    99m-technetium pyrophosphate scintigraphy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2022-01-19
    Completion
    2023-12-30
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Transthyretin Amyloid Cardiomyopathy
    Intervention99m-technetium pyrophosphate scintigraphy
    PhaseNot recorded
    Registry statusTerminated

  • Quantitative-imaging in Cardiac Transthyretin Amyloidosis

    NCT05776212 · start 2021-08-25

    Registered record
    Registry ID
    NCT05776212
    Conditions
    ATTR-CM
    Interventions
    18F-fluoride PET
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-08-25
    Completion
    2026-09-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATTR-CM
    Intervention18F-fluoride PET
    PhaseNot recorded
    Registry statusRecruiting

  • Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

    NCT04801329 · start 2021-06-29

    Registered record
    Registry ID
    NCT04801329
    Conditions
    ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
    Interventions
    Vyndamax (tafamidis 61mg)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-29
    Completion
    2026-04-21
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATTR-CM (Transthyretin Amyloid Cardiomyopathy)
    InterventionVyndamax (tafamidis 61mg)
    PhaseNot recorded
    Registry statusCompleted

  • The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients

    NCT04963985 · start 2021-06-01

    Registered record
    Registry ID
    NCT04963985
    Conditions
    Transthyretin Amyloidosis
    Interventions
    Tafamidis Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2023-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis
    InterventionTafamidis Pill
    PhasePhase 4
    Registry statusUnknown

  • The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

    NCT04828993 · start 2021-04-28

    Registered record
    Registry ID
    NCT04828993
    Conditions
    Transthyretin Amyloid Polyneuropathy (ATTR-PN)
    Interventions
    tafamidis meglumine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-28
    Completion
    2023-02-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloid Polyneuropathy (ATTR-PN)
    Interventiontafamidis meglumine
    PhasePhase 4
    Registry statusCompleted

  • Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

    NCT04849754 · start 2021-02-25

    Registered record
    Registry ID
    NCT04849754
    Conditions
    Cardiac Amyloidosis
    Interventions
    bone scintigraphy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-02-25
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Amyloidosis
    Interventionbone scintigraphy
    PhaseNot applicable
    Registry statusRecruiting

  • Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis

    NCT04535349 · start 2020-10-08

    Registered record
    Registry ID
    NCT04535349
    Conditions
    Amyloidosis Transthyretin
    Interventions
    Whole-body & CZT bone tracer imaging (SPECT)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2020-10-08
    Completion
    2025-06-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis Transthyretin
    InterventionWhole-body & CZT bone tracer imaging (SPECT)
    PhaseNot applicable
    Registry statusRecruiting

  • A Study to Determine the Bioequivalence of Two Doses of Tafamidis

    NCT04575116 · start 2020-09-17

    Registered record
    Registry ID
    NCT04575116
    Conditions
    Healthy
    Interventions
    Tafamidis free acid tablet; Tafamidis meglumine capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-17
    Completion
    2021-02-23
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis free acid tablet; Tafamidis meglumine capsule
    PhasePhase 1
    Registry statusCompleted

  • ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy

    NCT04513600 · start 2020-08-01

    Registered record
    Registry ID
    NCT04513600
    Conditions
    Transthyretin Amyloidosis
    Interventions
    Cardiac MRI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2023-08-01
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis
    InterventionCardiac MRI
    PhaseNot recorded
    Registry statusUnknown

  • A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics

    NCT04253353 · start 2020-02-06

    Registered record
    Registry ID
    NCT04253353
    Conditions
    Healthy Volunteers
    Interventions
    tafamidis; rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-06
    Completion
    2020-08-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventiontafamidis; rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Vyndaqel Capsules Special Investigation (ATTR-CM)

    NCT04108091 · start 2019-10-03

    Registered record
    Registry ID
    NCT04108091
    Conditions
    Transthyretin (TTR) Amyloid Cardiomyopathy
    Interventions
    Treatment for TTR amyloidosis; Treatment for TTR amyloidosis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-10-03
    Completion
    2025-03-27
    Enrolment
    1,214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin (TTR) Amyloid Cardiomyopathy
    InterventionTreatment for TTR amyloidosis; Treatment for TTR amyloidosis
    PhaseNot recorded
    Registry statusCompleted

  • Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

    NCT03431896 · start 2018-02-01

    Registered record
    Registry ID
    NCT03431896
    Conditions
    Amyloidosis; Amyloid; Amyloid Neuropathies, Familial; Amyloid Cardiomyopathy; Amyloid - Primary; Transthyretin Amyloidosis; AL Amyloidosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-01
    Completion
    2026-03-09
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Amyloid; Amyloid Neuropathies, Familial; Amyloid Cardiomyopathy +3 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

    NCT03266705 · start 2017-09-20

    Registered record
    Registry ID
    NCT03266705
    Conditions
    Healthy
    Interventions
    tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-20
    Completion
    2018-03-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontafamidis
    PhasePhase 1
    Registry statusCompleted